title: Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis.
abstract: Mixed cryoglobulinemia (MC) and glomerulonephritis are the most important extrahepatic manifestations of chronic hepatitis C virus (HCV) infection. In HCV-infected patients with MC, renal involvement worsens the overall prognosis because of a high incidence of infection or cardiovascular disease. The relationship between MC and HCV infection has prompted the use of antiviral therapy. Two patients with chronic HCV infection, type-II MC and membranoproliferative glomerulonephritis (MPGN), presenting as nephrotic syndrome were treated with interferon (IFN)-alpha (3 MU 3 times per week) and ribavirin (15 mg/kg daily) for 6 months. Laboratory tests included measurement of anti-HCV antibodies, HCV RNA, and HCV genotyping, and characterization of circulating cryoglobulins. A pretreatment renal biopsy was performed, and the histopathologic lesions were scored according to the index of disease activity. Viremia and cryoglobulinemia were suppressed in both patients. However, a complete remission of proteinuria was observed in 1 patient only. The evaluation of the renal biopsy specimens revealed a mild MPGN (activity score: 5/24) in the patient with remission of proteinuria and a severe MPGN (activity score: 15/24) in the patient who maintained a nephrotic-range proteinuria. Although a fully satisfactory treatment is not yet available, we feel that a reasonable therapeutic strategy for HCV-infected patients with MC nephritis could be as follows: (1) antiviral treatment alone for patients with a low-grade kidney involvement, and (2) a short-term course of steroids and cytotoxic drugs followed by antiviral therapy for acute exacerbations and/or rapidly progressive GN.
authors.affiliation: Departments of Clinical Medicine, Nephrology, and Health Sciences, University of Parma, Italy. garini@ipruniv.cce.unipr.it
authors.forename: G
authors.initials: G
authors.lastname: Garini
authors.forename: L
authors.initials: L
authors.lastname: Allegri
authors.forename: L
authors.initials: L
authors.lastname: Carnevali
authors.forename: W
authors.initials: W
authors.lastname: Catellani
authors.forename: P
authors.initials: P
authors.lastname: Manganelli
authors.forename: C
authors.initials: C
authors.lastname: Buzio
mesh_terms: D000328:Adult; D000368:Aged; D003449:Cryoglobulinemia / Q000150:complications*; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005260:Female; D015432:Glomerulonephritis, Membranoproliferative / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D006526:Hepatitis C / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D009404:Nephrotic Syndrome / Q000175:diagnosis; D012254:Ribavirin / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D016898:Interferon-alpha; D012254:Ribavirin